Uric-acid - Endogenous Metabolite - 生命科学试剂 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEUric acidCat. No.: HY-B2130CAS No.: 69-93-2分式: CHNO分量: 168.11作靶点: Endogenous Metabolite; Reactive Oxygen Species作通路: Metabolic Enzyme/Protease; Immunology/Inflammation; NF-B储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 mon

2、ths-20C 1 month溶解性数据体外实验 DMSO : 1 mg/mL (insoluble or slightly soluble)H2O : 0.1 mg/mL (insoluble)请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Uric acid种内 性抗氧化剂，可 除活性氧类化合物 (ROS)，包括单线态氧，氧由基和过氧亚硝酸盐。IC50 & Target Human Endogenous Metabolite体外研究 Uric acid is an endogenous antioxida

3、nt that scavenges reactive oxygen species (ROS) including singletoxygen, oxygen radicals, and peroxynitrite. Incubation with indomethacin significantly increasesmalondialdehyde (MDA) levels in Caco-2 cells compare to those not treated indomethacin. Incubation withboth indomethacin and Uric acid sign

4、ificantly decreases MDA levels compare to those grown in the presenceof indomethacin alone. Co-treatment of cells with indomethacin and Uric acid significantly decreases ROSlevels compare to those in cells incubated with indomethacin alone. Cell viability in Caco-2 cells treated withboth indomethaci

5、n and Uric acid is higher than that in cells treated with indomethacin alone. Uric acid has aprotective effect on indomethacin-induced intestinal cell changes through its antioxidant activity 1.体内研究When mice treated with indomethacin are concurrently administered Uric acid orally, ulcer areas are1/2

6、 Master of Small Molecules 您边的抑制剂师www.MedChemEsignificantly reduced, in a Uric acid dose-dependent manner. Indomethacin increases the ratio of crypt depthto villous height in the ileum, while the ratio is significantly lower when mice are concurrently administeredUric acid orally. Administration of

7、indomethacin also increases the histopathological score of tissue damagein the small intestine, while mice concurrently administered Uric acid orally has a significantly lowerhistopathological score. The ileal levels of malondialdehyde (MDA) in indomethacin-induced enteropathymodel mice orally admin

8、istered Uric acid are also significantly lower than the levels in mice administeredindomethacin alone 1.PROTOCOLCell Assay 1 Human colon carcinoma cells (Caco-2) are used and grown in Eagles minimum essential mediumsupplemented with 10% FBS, 1% non-essential amino acid mixture, and 1% Pen-Strep at 3

9、7C in ahumidified atmosphere with 5% CO2. Caco-2 cells are incubated with indomethacin in the presence orabsence of Uric acid for 24 or 48 hours 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal To evaluate the effect of oral administration of Ur

10、ic acid on NSAID-induced enteropathy, mice are given UricAdministration 1 acid (2.5, 10, 25, 100, or 250 mg/kg body weight) suspended in 0.5% carboxymethyl cellulose orally at 30minutes before, and 12 hours after indomethacin or vehicle treatment. To evaluate the effect ofintraperitoneal administrat

11、ion of inosinic acid plus potassium oxonate on NSAID-induced enteropathy, miceare given inosinic acid (500 mg/kg body weight) plus potassium oxonate (250 mg/kg body weight) 24intraperitoneally at 30 minutes before, and 12 hours after indomethacin or vehicle treatment 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Yasutake Y, et al. Uric acid ameliorates indomethacin-induced enteropathy in mice through its antioxidant activity. J GastroenterolHepatol. 2017 Nov;32(11):1839-1845.McePdfHeightCaution: Prod